Clinical Applications and Challenges of Tumor Companion Diagnostic Factor Detection Kits in Multi-Gene Combined Testing

Technical Basis for Multiplex Gene Testing

The core value of tumor companion diagnostic factor detection kits lies in providing a basis for the applicability of targeted therapy or immunotherapy by analyzing specific gene mutations, fusions, or changes in expression levels. Multiplex gene testing typically employs technical platforms such as high-throughput sequencing, real-time fluorescence PCR, or digital PCR to simultaneously assess multiple key factors in a single experiment. For example, in non-small cell lung cancer, common detection panels include EGFR, ALK, ROS1, BRAF, MET and other gene alterations, as well as PD-L1 protein expression levels. These factors each correspond to different targeted drugs or immunotherapy regimens, and multiplex testing can improve detection efficiency and avoid repeated sampling. The design of the kit must balance sensitivity and specificity, generally requiring a limit of detection within the range of 1%-5% variant allele frequency, and must undergo rigorous performance validation.

Key Detection Factors and Their Clinical Significance

The companion diagnostic factors required for different tumor types vary in emphasis. For example, in colorectal cancer, RAS/BRAF gene status is detected to guide anti-EGFR monoclonal antibody therapy; in breast cancer, HER2 amplification/overexpression status determines the indications for targeted drugs such as trastuzumab; and in gastric cancer, HER2 testing is equally critical. In addition, microsatellite instability and tumor mutational burden, as pan-cancer markers related to immunotherapy, have become common detection items in next-generation kits. The detection results of each factor must be interpreted in conjunction with clinicopathological features and cannot be used alone as an absolute standard for judging therapeutic efficacy. Kit instructions typically clearly indicate the clinically relevant reference ranges and positive cutoff thresholds for each factor, but in practical application, confirmation by professional laboratory personnel based on internal quality control data is still required.

Application of Kits in Treatment Decision-Making

Tumor companion diagnostic factor detection kits are mainly used for molecular typing of newly diagnosed patients and for monitoring after drug resistance. At the initial diagnosis stage, test results can guide the selection of first-line targeted drugs or immunotherapeutic agents. For example, if a patient with non-small cell lung cancer is found to have an EGFR sensitizing mutation, an epidermal growth factor receptor tyrosine kinase inhibitor is preferentially recommended. After drug resistance, treatment strategies can be adjusted by detecting resistance mutations (such as EGFR T790M or KRAS G12C) through repeat biopsy or liquid biopsy. The timeliness of kit testing is crucial, generally requiring reports to be issued within 3-5 working days to facilitate clinical decision-making. It should be noted that the kit is for in vitro diagnostic use only, and the results should be comprehensively referenced alongside other laboratory tests and clinical assessments.

Current Challenges and Response Strategies

The promotion of multiplex gene testing still faces several challenges. The first is sample quality: issues such as DNA degradation in formalin-fixed paraffin-embedded tissue specimens and insufficient tumor cell content may affect detection accuracy. The second is the complexity of data interpretation: whether a variant site has clinical significance and whether it is a driver mutation or a passenger mutation must be judged based on authoritative databases and expert consensus. In addition, differences in detection scope, sensitivity, and interpretation standards among different kits limit the comparability of results. To address these challenges, laboratories should establish a comprehensive quality control system, regularly participate in external quality assessment, and use kits registered with the National Medical Products Administration. At the same time, clinical and pathology departments need to strengthen communication to ensure standardized processes for test requests and result reporting. In the future, with the advancement of standardization and the maturation of artificial intelligence-assisted interpretation technologies, multiplex gene testing using tumor companion diagnostic factor detection kits is expected to be applied more widely in primary healthcare institutions.